Skip to main content
HairCited
The hair loss did not improve or showed a modest improvement in 37.80% (95% CI=24.88-52.71) of all patients. Further subgroup analysis showed that the rate was 31.93% (95% CI=17.17-51.49) in the combined therapy and 46.73% (95% CI=30.93-63.21) in the mono
Figure 4. The hair loss did not improve or showed a modest improvement in 37.80% (95% CI=24.88-52.71) of all patients. Further subgroup analysis showed that the rate was 31.93% (95% CI=17.17-51.49) in the combined therapy and 46.73% (95% CI=30.93-63.21) in the monotherapy. Nevertheless, heterogeneity was present in both overall (I2=74%; P-value=0.004) and subgroup estimates (Figure 3).

Beschreibung

Pooled analysis indicating that hair loss did not improve or showed only modest improvement in 37.80% (95% CI: 24.88-52.71%) of patients treated with oral spironolactone, with subgroup analyses revealing variable response rates.

More Figures from This Paper

Forest plot or pooled analysis from the spironolactone meta-analysis, presenting combined efficacy data across studies examining oral spironolactone for treating female pattern hair loss.

Figure 2

Forest plot or pooled analysis from the spironolactone meta-analysis, presenting combined efficacy data across studies examining oral spironolactone for treating female pattern hair loss.

forest_plot
Risk of bias or quality assessment for studies included in the spironolactone and female pattern hair loss meta-analysis, evaluating methodological rigor across the evidence base.

Figure 3

Risk of bias or quality assessment for studies included in the spironolactone and female pattern hair loss meta-analysis, evaluating methodological rigor across the evidence base.

chart
Safety outcomes or adverse event analysis from the spironolactone meta-analysis, summarizing the tolerability profile of oral spironolactone when used for female pattern hair loss.

Figure 5

Safety outcomes or adverse event analysis from the spironolactone meta-analysis, summarizing the tolerability profile of oral spironolactone when used for female pattern hair loss.

chart

Figure 4

Forest Plot
694 × 338px · 53,8 KB

Source Paper

The Efficacy and Safety of Oral Spironolactone in the Treatment of Female Pattern Hair Loss: A Systematic Review and Meta-Analysis.

Cureus (2023)

PMID: 37719557

DOI: 10.7759/cureus.43559

Cite This Figure

![Figure 4: Pooled analysis indicating that hair loss did not improve or showed only modest improvement in 37.80% (95% CI: 24.88-52.71%) of patients treated with oral spironolactone, with subgroup analyses revealing variable response rates.](https://pdfs.citedhealth.com/figures/37719557/174.png)

> Source: Majed Aleissa "The Efficacy and Safety of Oral Spironolactone in the Treatment of Female Patter." *Cureus*, 2023. PMID: [37719557](https://pubmed.ncbi.nlm.nih.gov/37719557/)
<figure>
  <img src="https://pdfs.citedhealth.com/figures/37719557/174.png" alt="Pooled analysis indicating that hair loss did not improve or showed only modest improvement in 37.80% (95% CI: 24.88-52.71%) of patients treated with oral spironolactone, with subgroup analyses revealing variable response rates." />
  <figcaption>Figure 4. Pooled analysis indicating that hair loss did not improve or showed only modest improvement in 37.80% (95% CI: 24.88-52.71%) of patients treated with oral spironolactone, with subgroup analyses revealing variable response rates.<br>  Source: Majed Aleissa "The Efficacy and Safety of Oral Spironolactone in the Treatment of Female Patter." <em>Cureus</em>, 2023. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37719557/">37719557</a></figcaption>
</figure>

Verwandte Evidenz

A
Spironolacton für Androgenetische Alopezie

Bewertung A · 45 Studien

 A
Spironolacton für Weiblicher Haarausfall

Bewertung A · 45 Studien